PB 51 of 2012
National Health (Weighted average disclosed price – third transitional disclosure cycle) Amendment Determination 2012
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.
Dated 20 July 2012
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Determination
(1) This Determination is the National Health (Weighted average disclosed price – third transitional disclosure cycle) Amendment Determination 2012.
(2) This Determination may also be cited as PB 51 of 2012.
2 Commencement
This Determination commences on the day after it is registered.
3 Amendments to PB 12 of 2012
Schedule 1 amends the National Health (Weighted average disclosed price – third transitional disclosure cycle) Determination 2012 (PB 12 of 2012).
Schedule 1 Amendments
[1] Schedule 1, After
17
Bisoprolol
Tablet containing bisoprolol fumarate 10 mg
Oral
APO-Bisoprolol
44.24
47.57
insert:
17A
Bisoprolol
Tablet containing bisoprolol fumarate 10 mg
Oral
Beprol 10
44.24
47.57
[2] Schedule 1, After
19
Bisoprolol
Tablet containing bisoprolol fumarate 10 mg
Oral
Bicor
44.24
47.57
insert:
19A
Bisoprolol
Tablet containing bisoprolol fumarate 10 mg
Oral
Biso 10
44.24
47.57
[3] Schedule 1, After
26
Bisoprolol
Tablet containing bisoprolol fumarate 2.5 mg
Oral
APO-Bisoprolol
28.32
30.45
insert:
26A
Bisoprolol
Tablet containing bisoprolol fumarate 2.5 mg
Oral
Beprol 2.5
28.32
30.45
[4] Schedule 1, After
28
Bisoprolol
Tablet containing bisoprolol fumarate 2.5 mg
Oral
Bicor
28.32
30.45
insert:
28A
Bisoprolol
Tablet containing bisoprolol fumarate 2.5 mg
Oral
Biso 2.5
28.32
30.45
[5] Schedule 1, After
35
Bisoprolol
Tablet containing bisoprolol fumarate 5 mg
Oral
APO-Bisoprolol
35.39
38.05
insert:
35A
Bisoprolol
Tablet containing bisoprolol fumarate 5 mg
Oral
Beprol 5
35.39
38.05
[6] Schedule 1, After
37
Bisoprolol
Tablet containing bisoprolol fumarate 5 mg
Oral
Bicor
35.39
38.05
insert:
37A
Bisoprolol
Tablet containing bisoprolol fumarate 5 mg
Oral
Biso 5
35.39
38.05
[7] Schedule 1, After
47
Doxorubicin
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial
Injection/intravesical
Accord Doxorubicin
4.61
4.96
omit:
48
Doxorubicin
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial
Injection/intravesical
Adriamycin Solution
4.61
4.96
[8] Schedule 1, After
51
Doxorubicin
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 mL single dose vial
Injection/intravesical
Doxorubicin Ebewe
38.97
41.90
omit:
52
Doxorubicin
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial
Injection/intravesical
Adriamycin Solution
8.24
8.86
[9] Schedule 1, After
88
Levetiracetam
Tablet 1 g
Oral
Keppra
96.84
104.12
insert:
88A
Levetiracetam
Tablet 1 g
Oral
Kerron 1000
96.84
104.12
[10] Schedule 1, After
99
Levetiracetam
Tablet 250 mg
Oral
Keppra
34.86
37.48
insert:
99A
Levetiracetam
Tablet 250 mg
Oral
Kerron 250
34.86
37.48
[11] Schedule 1, After
110
Levetiracetam
Tablet 500 mg
Oral
Keppra
58.12
62.49
insert:
110A
Levetiracetam
Tablet 500 mg
Oral
Kerron 500
58.12
62.49
[12] Schedule 1, After
149
Meloxicam
Tablet 7.5 mg
Oral
Terry White Chemists Meloxicam 7.5 mg
6.82
7.33
omit:
150
Mitozantrone
Injection 10 mg (as hydrochloride) in 5 mL
Injection
Pfizer Australia Pty Ltd
53.34
57.35
[13] Schedule 1, After
155
Mitozantrone
Injection 25 mg (as hydrochloride) in 12.5 mL
Injection
Onkotrone
133.29
143.31
omit:
156
Mitozantrone
Injection 25 mg (as hydrochloride) in 12.5 mL
Injection
Pfizer Australia Pty Ltd
133.29
143.31
[14] Schedule 1, After
160
Ondansetron
I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL
Injection
Onsetron
1.93
2.08
omit:
161
Ondansetron
I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL
Injection
Pfizer Australia Pty Ltd
1.93
2.08
[15] Schedule 1, After
166
Ondansetron
I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL
Injection
Onsetron
3.06
3.29
omit:
167
Ondansetron
I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL
Injection
Pfizer Australia Pty Ltd
3.06
3.29
[16] Schedule 1, After
174
Oxaliplatin
Powder for I.V. infusion 100 mg
Injection
Oxaliplatin Link
79.14
85.09
omit:
175
Oxaliplatin
Powder for I.V. infusion 100 mg
Injection
Winthrop Oxaliplatin
79.14
85.09
[17] Schedule 1, After
185
Oxaliplatin
Solution concentrate for I.V. infusion 100 mg in 20 mL
Injection
Eloxatin
79.14
85.09
insert:
185A
Oxaliplatin
Solution concentrate for I.V. infusion 100 mg in 20 mL
Injection
Oxaliccord
79.14
85.09
[18] Schedule 1, After
191
Oxaliplatin
Solution concentrate for I.V. infusion 50 mg in 10 mL
Injection
Eloxatin
40.97
44.05
insert:
191A
Oxaliplatin
Solution concentrate for I.V. infusion 50 mg in 10 mL
Injection
Oxaliccord
40.97
44.05
[19] Schedule 2, After
10
Fosinopril with Hydrochlorothiazide
Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg
Oral
APO-Fosinopril HCTZ 10/12.5
11.38
omit:
11
Fosinopril with Hydrochlorothiazide
Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg
Oral
Fosinopril/HCT Sandoz 10mg/12.5mg
11.38
[20] Schedule 2, After
16
Fosinopril with Hydrochlorothiazide
Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg
Oral
Fosetic 20/12.5
16.72
omit:
17
Fosinopril with Hydrochlorothiazide
Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg
Oral
Fosinopril/HCT Sandoz 20mg/12.5mg
16.72
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.
